Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer
Yujun Zhang, Liwen Xiong, Fangfang Xie, Xiaoxuan Zheng, Ying Li, Lei Zhu, Jiayuan Sun, Yujun Zhang, Liwen Xiong, Fangfang Xie, Xiaoxuan Zheng, Ying Li, Lei Zhu, Jiayuan Sun
Abstract
Background: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has been considered as an effective treatment in epidermal growth factor receptor-mutant (EGFR-mutant) advanced non-small cell lung cancer (NSCLC). However, most patients develop acquired resistance eventually. Here, we compared and analyzed the genetic alterations between tissue assay and circulating tumor DNA (ctDNA) and further explored the resistance mechanisms after EGFR-TKI treatment.
Methods and materials: Amplification refractory mutation system-polymerase chain reaction (ARMS-PCR), Cobas® ARMS-PCR and next-generation sequencing (NGS) were performed on tissue samples after pathological diagnosis. Digital droplet PCR (ddPCR) and NGS were performed on plasma samples. The association between genetic alterations and clinical outcomes was analyzed retrospectively.
Results: Thirty-seven patients were included. The success rate of re-biopsy was 91.89% (34/37). The total detection rate of EGFR T790M was 62.16% (23/37) and the consistency between tissue and ctDNA was 78.26% (18/23). Thirty-four patients were analyzed retrospectively. For tissue re-biopsy, 24 patients harbored concomitant mutations. Moreover, tissue re-biopsy at resistance showed 21 patients (21/34, 61.76%) had the concomitant somatic mutation. The three most frequent concomitant mutations were TP53 (18/34, 52.94%), MET (4/34, 11.76%), and PIK3CA (4/34, 11.76%). Meanwhile, 21 patients (21/34, 61.76%) with EGFR T790M mutation. Progression-free survival (PFS) and overall survival (OS) were better in patients with T790M mutation (p = 0.010 and p = 0.017) or third-generation EGFR-TKI treatment (p < 0.0001 and p = 0.073). Interestingly, concomitant genetic alterations were significantly associated with a worse prognosis for patients with EGFR T790M mutation receiving third-generation EGFR-TKIs (p = 0.037).
Conclusions: Multi-platforms are feasible and highly consistent for re-biopsy after EGFR-TKI resistance. Concomitant genetic alterations may be associated with a poor prognosis for patients with EGFR T790M mutation after third-generation EGFR-TKIs.
Trial registration: ClinicalTrials.gov NCT03309462.
Keywords: epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); genetic alterations; non-small cell lung cancer (NSCLC); re-biopsy.
Conflict of interest statement
The authors declare that they have no competing interests.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Figures
![FIGURE 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8290257/bin/CAM4-10-4697-g003.jpg)
![FIGURE 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8290257/bin/CAM4-10-4697-g004.jpg)
![FIGURE 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8290257/bin/CAM4-10-4697-g001.jpg)
![FIGURE 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8290257/bin/CAM4-10-4697-g002.jpg)
![FIGURE 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8290257/bin/CAM4-10-4697-g005.jpg)
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424.
- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small‐cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539‐4544.
- Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823‐859.
- Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non‐small‐cell lung cancer. Drug Des Devel Ther. 2014;8:1595‐1611.
- Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non‐small‐cell lung cancer. J Clin Oncol. 2010;28:357‐360.
- Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M‐mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046‐1061.
- Attili I, Karachaliou N, Conte P, Bonanno L, Rosell R. Therapeutic approaches for T790M mutation positive non‐small‐cell lung cancer. Expert Rev Anticancer Ther. 2018;18:1021‐1030.
- National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Non‐small cell lung cancer. ; 2020. Accessed 29 February, 2020.
- Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Drug resistance to EGFR inhibitors in lung cancer. Chemotherapy. 2016;61:223‐235.
- Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR‐mutant non‐small‐cell lung cancer after acquired resistance to EGFR‐TKI. J Thorac Oncol. 2015;10:1553‐1559.
- Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co‐occurring genetic alterations in advanced‐stage EGFR‐mutant lung cancers. Nat Genet. 2017;49:1693‐1704.
- Hong S, Gao F, Fu S, et al. Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR‐mutant advanced non‐small cell lung cancer. JAMA Oncol. 2018;4:739‐742.
- Nosaki K, Satouchi M, Kurata T, et al. Re‐biopsy status among non‐small cell lung cancer patients in Japan: a retrospective study. Lung Cancer. 2016;101:1‐8.
- Kirita K, Izumo T, Matsumoto Y, Hiraishi Y, Tsuchida T. Bronchoscopic re‐biopsy for mutational analysis of non‐small cell lung cancer. Lung. 2016;194:371‐378.
- Chouaid C, Dujon C, Do P, et al. Feasibility and clinical impact of re‐biopsy in advanced non small‐cell lung cancer: a prospective multicenter study in a real‐world setting (GFPC study 12–01). Lung Cancer. 2014;86:170‐173.
- Bosc C, Ferretti GR, Cadranel J, et al. Rebiopsy during disease progression in patients treated by TKI for oncogene‐addicted NSCLC. Target Oncol. 2015;10:247‐253.
- Hochmair MJ, Buder A, Schwab S, et al. Liquid‐biopsy‐based identification of EGFR T790M mutation‐mediated resistance to Afatinib treatment in patients with advanced egfr mutation‐positive NSCLC, and subsequent response to osimertinib. Target Oncol. 2019;14:75‐83.
- McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613‐628.
- Xie F, Zhang Y, Mao X, et al. Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment‐naive advanced non‐squamous non‐small cell lung cancer patients. Lung Cancer. 2018;121:54‐60.
- Sherwood J, Dearden S, Ratcliffe M, Walker J. Mutation status concordance between primary lesions and metastatic sites of advanced non‐small‐cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res. 2015;34:92.
- Wang S, Wang Z. Meta‐analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non‐small cell lung cancer. Clin Oncol (R Coll Radiol). 2015;27:30‐39.
- Mao X, Zhang Z, Zheng X, et al. Capture‐based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA‐releasing capability in advanced lung cancer. J Thorac Oncol. 2017;12:663‐672.
- Wan R, Wang Z, Lee JJ, et al. Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non‐small cell lung cancer. J Thorac Oncol. 2017;12:1376‐1387.
- Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD‐1 inhibitor resistance in KRAS‐mutant lung adenocarcinoma. Cancer Discov. 2018;8:822‐835.
- Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR‐mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69:3256‐3261.
- Kim TM, Song A, Kim D‐W, et al. Mechanisms of acquired resistance to AZD9291: a mutation‐selective, Irreversible EGFR Inhibitor. J Thorac Oncol. 2015;10:1736‐1744.
- Sequist LV, Waltman BA, Dias‐Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
- Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR‐TKI therapy in 155 patients with EGFR‐mutant lung cancers. Clin Cancer Res. 2013;19:2240‐2247.
- Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid‐based assay. Clin Cancer Res. 2011;17:1169‐1180.
- Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M‐positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527‐1534.
- Lin C‐C, Shih J‐Y, Yu C‐J, et al. Outcomes in patients with non‐small‐cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018;6:107‐116.
- Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma‐rationale for comprehensive mutation profiling. Mol Cancer Ther. 2012;11:485‐491.
- Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide‐3‐Kinase Catalytic Alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non‐small cell lung cancer. J Thorac Oncol. 2011;6:707‐715.
Source: PubMed